Contribute to the Site - CN

Blog
Article

Cancer Network's content includes news, articles from the journal ONCOLOGY, blogs, Image IQs, case studies, videos, and podcasts.

Please send any inquiries or contributions to our managing editor, Ian Ingram: ian.ingram@ubm.com

Blogging

Interested in blogging? We are looking for oncologists interested in contributing regular commentary about life in practice and the ever-changing world of oncology and hematology. Our bloggers generally contribute monthly.

Case Studies

Have a compelling case to share? Submit cases to be posted to our Case Studies section, and we’ll send you $50. Cases must include images with descriptions and a short write-up that includes history, findings, diagnosis, and a discussion.

Image IQ

Have a case that would work great in quiz format? Submit your case to be posted to our Image IQ section, and we’ll send you $75. Image IQs must include an image, clinical history, a question with multiple answer choices, and a discussion of the correct answer.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.